Goldman Sachs, Pfizer fall premarket; Morgan Stanley, Coinbase rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
RBC Capital on Goldman Sachs (GS): 'remain best in class'
January 18, 2023 7:20 AM ESTRBC Capital analyst Gerard Cassidy reiterated a Sector Perform rating and $370.00 price target on Goldman Sachs (NYSE: GS).
The analyst comments "GS is one of the preeminent global investment banks but even with its leading position, market conditions negatively impacted nearly all of its... More
Pfizer (PFE) requires an expense reset for potential upside - Wells Fargo
January 17, 2023 9:57 AM ESTWells Fargo analyst Mohit Bansal downgraded shares of Pfizer (NYSE: PFE) to Equal Weight from Overweight, cutting the firm's price target on the stock to $50 from $54 per share in a note to clients on Tuesday.
Pfizer shares have declined more than 3%... More
